Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHOD AND DEVICE FOR TREATMENT AND/OR PREVENTION OF OPHTHALMIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2021/069962
Kind Code:
A1
Abstract:
This invention relates to the field of ophthalmology and prevention and medical treatment of various ophthalmic diseases. The object of the invention is to provide the method for improving treatment quality and efficacy The method of treatment and prevention of ophthalmic diseases includes an integrated eye exposure to specific trains of color pulses of different wavelengths and eye exposure to the pulsed magnetic field through generation of a train of pulses synchronously with optical pulses. The device for implementing the method includes a set of light sources of different wavelengths and also pulse magnetic inductors configured to produce effect of exposure of eyes to magnetic pulses, a control device and pulse modulators. A technical result resides in the improved efficacy of treatment by improving hemodynamics in the retina, ophthalmic nerve and capillary perfusion resulting in the increased delivery of drugs, enhancing functional activity of nerve cells.

Inventors:
PLETNEV SERGEY (BY)
PEFTIEV VLADIMIR (BY)
Application Number:
PCT/IB2019/058716
Publication Date:
April 15, 2021
Filing Date:
October 12, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
PLETNEV SERGEY (BY)
PEFTIEV VLADIMIR (BY)
International Classes:
A61F9/00; A61N2/04; A61N5/06
Foreign References:
RU2102951C11998-01-27
RU2033208C11995-04-20
Attorney, Agent or Firm:
VINOGRADOV, Sergey (BY)
Download PDF:
Claims:
CLAIMS

1. The method for treatment and/or prevention of ophthalmic diseases, including the integrated eye exposure to specific trains of color pulses of different wavelengths and exposure to magnetic field, characterised in that the magnetic field exposure is performed by a train of pulses synchronously with optical pulses.

2. The method according to claim 1, characterised in that the magnetic pulse repetition frequency is multiple of the optical pulse repetition frequency.

3. The method according to claim 1, characterised in that magnetic field exposure is performed by a train of pulses being synchronous with optical pulses.

4. The method according to claim 1 characterised in that the magnetic pulse modulation frequency is multiple of the optical pulse repetition frequency.

5. The device for implementing the method according to claim 1, comprising glasses, a set of light sources of different wavelengths configured for the eye light exposure, a control and synchronizing device and pulse modulators of light and magnetic pulses.

6. The device according to claim 5, characterised in that the device additionally comprises a pulsed magnetic field inductor disposed on a head occipital lobe, with said inductor being projected on the brain visual center and connected with the control and synchronizing device.

Description:
METHOD AND DEVICE FOR TREATMENT AND/OR PREVENTION OF

OPHTHALMIC DISEASES

This invention relates to the field of medicine, more particularly to ophthalmology, and is used in prevention and medical treatment of various ophthalmic diseases (dystrophic, inflammatory and myopia, hyperopia, etc.) using physiotherapeutic means.

Methods for treatment of ophthalmic nerve and retinal pathologies by exposing eyes to a pulsed magnetic field are known in the prior art (RU Patent No. 2062128 published 20.06.1996). The device allows deep-seated internal structures, in particular an optical nerve and blood vessels surrounding the surface thereof to be exposed to the alternating magnetic field, with said field induction being 20-25 mTl.

In this case, the magnetic field pulse exposure mainly effects local molecules, cellular structures and vessels and produces predominantly a stimulatory action on metabolic processes in these structures in the local region. In addition, a large-size and cross-section core is used in the electric magnet, with procedures being mainly preventive and longlasting.

A combined method of treatment of dystrophic disorders of the retina and ophthalmic nerve is also known in the prior art, RU Patent No. 2406469, residing in the use of electromagnetic oscillation by exposing eyes to magnetic pulses generated by a magnetic inductor and exposing biologically active points to specific electromagnetic frequencies by attaching electrodes to said points. The apparatus uses the “Expert-Voll” device which exposes biologically active points (BAPs) to electrical frequencies. BAPs are also simultaneously exposed to the magnetic field. R. Volfs method depends on BAPs proper selection and, therefore, it is not always effective and requires a protracted course of therapy.

Methods of treatment using eye exposure to the electromagnetic optical radiation of different wavelengths are also known in the prior art.

The prior art discloses the method for eye disorder treatment and “Oko-Medius” apparatus, RU Patent No. 2280425, subject to which the patient’s eyes are exposed to at least two of the following four electromagnetic radiation pulse trains: a train of infrared radiation pulses with a wavelength being in the range of 730÷980 nm; a train of visible light spectrum pulses in the red color region with the wavelength range of 620÷670 nm; a train of visible light spectrum pulses in the green color region with the wavelength range of 520÷570 nm; a train of visible light spectrum pulses in the blue color region with the wavelength range of 400÷450 nm, with each train having a pulse ratio of 0.7÷5 and a total duration of 1.5÷3 minutes, while the power of each pulse is 0.5÷1 mW.

This apparatus also requires a protracted course of therapy and is not very effective at late stages of such diseases as diabetes.

The method and device being closest to the proposed technical solution are the method and device for treatment the ophthalmic diseases by using Professor O.P. Pankov’s glasses disclosed in the patent specification RU 2102951 Cl published 27.01.1998, IPC-7 A 61 F 2/00. Said method for ophthalmic diseases treatment provides the use of special glasses generating a light electromagnetic field and a permanent magnetic field to which eyes are disposed, with the patient’s eyes being exposed to the permanent magnetic field via the action of permanent magnets on the patient’s eyes corporeal acupuncture points, while the permanent magnetic field intensity is not in excess of 40 mTl. The glasses comprise magnets disposed in the glasses rim along the lens holder perimeter. The glasses also comprise n electromagnetic radiation sources, with the radiation frequency ranging from near-infrared radiation to ultraviolet radiation.

The essence of this invention resides in the use of spectral radiation and their pulse repetitions in various combinations generated by electromagnetic radiation sources depending on the cases of the recipient’s eye ophthalmic pathologies, since the character of eye tissue absorption varies with the laser radiation wavelength and presence of pathology, as well as with location of the radiation source and also an output fiber optic end face in direct proximity to the eye surface.

In addition, while reducing laser beam reflection, the permanent magnetic field effect combined with laser radiation improves plasma, tissue, lymphatic and sodium-potassium equilibrium by normalizing the eye capillary permeable tissue. Besides, several glasses sizes and different values of the permanent magnetic field intensity are provided.

In addition, eye tissues will be locally exposed to a biostimulatory action of both the magnetic field and the laser radiation.

However, sufficient treatment efficacy is not achieved by using permanent magnets.

The object of the invention is to provide the method for improving treatment quality and efficacy.

The above object is to be achieved as described herein below: The method of treatment and prevention of ophthalmic diseases includes an integrated eye exposure to specific trains of color pulses of different wavelengths and eye exposure to the pulsed magnetic field through generation of a train of pulses synchronously with optical pulses.

The method is also characterized in that the magnetic pulse repetition frequency is multiple of the optical pulse repetition frequency.

It is most optimal to provide the magnetic field exposure by serious of magnetic pulses synchronous with optical pulses.

In this case, the magnetic pulse repetition frequency may be multiple of the optical pulse repetition frequency.

The device for implementing the method includes a set of light sources of different wavelengths and also pulse magnetic inductors configured to produce effect of exposure of eyes to magnetic pulses, a control device and pulse modulators.

To form different exposure parameters, it is proposed to use a controller and a database of pre obtained values of light and magnetic exposure parameters being efficient for treatment and prevention of respective ophthalmic diseases and/or pathologies.

Additionally synchronizing magnetic pulses to which a visual center located in the brain occipital lobe is exposed contributes to recovery and improvement of visual synapses conduction and visual quality improvement.

A technical result resides in the improved efficacy of treatment of patients with dystrophic retina and ophthalmic nerve disorders by improving hemodynamics in the retina, ophthalmic nerve and capillary perfusion resulting in the increased delivery of drugs, enhancing functional activity of nerve cells.

Fig.1 shows a scheme of one of the embodiments of the device.

The device comprises glasses 1 equipped with light sources 2 disposed thereon, with the light sources being a combination of infrared(IR), red, green and blue light-emitting diodes controlled by an optical pulse modulator 3. Broadband inductors 4 are also disposed on glasses eyepieces which generate the pulsed magnetic field for the eye exposure and are excited by the magnetic pulse modulators 5.

The controller 6 is configured to control and synchronize the operation of modulators 3 and 5.

A controller 6 is programmed and controlled by a processor 7 connected to the database 8 containing preliminary obtained values of light and magnetic exposure parameters being effective for treatment and prevention of respective ophthalmic diseases and/or pathologies.

A physician sets specific parameters of treatment regimen via an interface of the processor 7 subject to the preliminary obtained diagnosis and efficient parameters from the database 8.

An auxiliary inductor 9 projecting on the brain visual center in the occipital region and secured on a strap 10 may be also additionally and synchronously used. In this case, the inductor 9 is synchronously excited by the pulsed magnetic field modulator 5.

The device operates and provides implementation of the method in the manner described below.

The data on effective optical pulse parameters obtained by Professor Pankov and data on effective low-frequency pulse magnetic therapy parameters (LFPMT) accumulated by Professor Pletnev, as well as the data obtained from the integrated exposure studies are included into the database 8.

According to the physician-determined diagnosis, parameters from the database 8 are processed by the processor 7 and supplied to the controller 6 which sets modes and synchronizes the operation of modulators 3 and 5.

For example, if according to RU 2280425 an effective light pulse repetition frequency for a number of diseases is 0.8 Hz, then an effective magnetic pulse repetition frequency may be multiple - 8 Hz, while the modulation frequency in the magnetic pulse is 80 Hz. Furthermore, light pulse exposure intervals may be distributed within the interval of the LFPMT procedure both at the beginning, during and at the end thereof.

The exposure using, for example, 80 Hz IR pulses, 8 Hz magnetic pulse frequency and 40-200 Hz magnetic modulation may be synchronized in a similar manner.

When using such an integrated exposure in addition to the light therapy, the synchronous magnetic therapy improves hemodynamics in retina, ophthalmic nerve and capillary perfusion enhancing a functional activity of nerve cells. This, in its turn, substantially improves efficacy of perception and conductivity of light pulse signals (non-analogous result). Moreover, synchronous additional exposure of the brain visual center to magnetic pulses also improves conductivity of the light pulse exposure channels (non-analogous result).

Treatment efficacy substantially improves in combination with drugs, since the increased capillary perfusion and permeability of cellular membranes during the magnetotherapeutic procedure improves drug delivery efficiency.

Efficiency of the method and device is also demonstrated under various general pathological conditions. For example, in cases of vision impairment due to diabetes-related complications.

Example 1. A patient K. diagnosed with type 1 diabetes neuropathy. 12 sessions were conducted under conditions of exposure to red and IR light and 8 Hz magnetic therapy. Magnetic field - 25 mTl. Specifically, the duration of the l st -3 rd sessions - 12 minutes each, 4 th -6 th sessions - 18 minutes each, 7 th -9 th sessions - 22 minutes each, 10 th - 12 th sessions - 12 minutes each. This resulted in the restoration of blood supply and pain syndrome disappearance. General condition substantially improved and blood sugar level reduced.

Example 2. A patient M. diagnosed with type 2 diabetes neuropathy, keratitis. 10 procedures using green light and 8 Hz magnetic therapy exposure were conducted. Magnetic field - 25 Tl. Specifically, the duration of the l st -3 rd sessions - 10 minutes each, 4 th - 7 th session - 12 minutes each and 8 th - 10 th sessions - 12 minutes each. The treatment resulted in the eyesight recovery and pain syndrome and eye swelling disappearance. General condition substantially improved and blood sugar level reduced.

After treatment procedures were also conducted prophylactically in the process of rehabilitation.

Preventing procedures may also be used in case of deseases like diabetes and others.

Therefore, the claimed invention provides an integrated method of synchronous light and pulse magnetic therapy, which is a new method and involves an inventive step. The industrial use of the invention is provided by using a universal programmable device which is described in the application and shown in the example, and it also may be implemented in the form of a series of specialized devices for treatment of specific group of diseases. In this case, the operation of specific devices will be controlled by a controller with fixed or programmable parameters. Such devices may be portable and self-contained and may be widely used in the outpatient setting.